Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

Atherosclerosis

Volumn 261, Issue , 2017, Pages 144-152

  Arai, Hidenori ^a   Yamashita, Shizuya ^b,c   Yokote, Koutaro ^d   Araki, Eiichi ^e   Suganami, Hideki ^f   Ishibashi, Shun ^g  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Rinku General Medical Center   (Japan)

^d CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f KOWA COMPANY LTD   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Combination therapy; Dyslipidaemia; K 877; Pemafibrate; SPPARM ; Statin; Triglyceride

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; CREATININE; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEMAFIBRATE; PITAVASTATIN; ROSUVASTATIN; TRIACYLGLYCEROL; URIC ACID; ANTILIPEMIC AGENT; BENZOXAZOLE DERIVATIVE; BIOLOGICAL MARKER; BUTYRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; K-877 COMPOUND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; QUINOLINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ANKLE FRACTURE; ARTICLE; BILE DUCT CANCER; BODY MASS; BRAIN INFARCTION; CHOLESTEROL BLOOD LEVEL; COLON CANCER; COLON POLYP; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENTERITIS; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GALLBLADDER CANCER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOMA; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VERTEBRAL CANAL STENOSIS; AGED; AGONISTS; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HYPERTRIGLYCERIDEMIA; JAPAN; METABOLISM; MULTICENTER STUDY; SIGNAL TRANSDUCTION; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BENZOXAZOLES; BIOMARKERS; BUTYRATES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; PPAR ALPHA; QUINOLINES; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; YOUNG ADULT;

EID: 85017401208     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2017.03.032     Document Type: Article

References (46)

1. Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
2. Libby, P., The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46 (2005), 1225–1228.
3. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 129 (2014), S1–S45.
4. Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J. Atheroscler. Thromb. 20 (2013), 517–523.
5. Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and european atherosclerosis society (EAS) developed with the special contribution of the european assocciation for cardiovascular prevention & rehabilitation (EACPR). Atherosclerosis 253 (2016), 281–344.
6. Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
7. Bansal, S., Buring, J.E., Rifai, N., Mora, S., Sacks, F.M., et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298 (2007), 309–316.
8. Carey, V.J., Bishop, L., Laranjo, N., Harshfield, B.J., Kwiat, C., et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am. J. Cardiol. 106 (2010), 757–763.
9. Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K.K., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000.
10. Jorgensen, A.B., Frikke-Schmidt, R., West, A.S., Grande, P., Nordestgaard, B.G., et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur. Heart J. 34 (2013), 1826–1833.
11. Nordestgaard, B.G., Benn, M., Schnohr, P., Tybjaerg-Hansen, A., Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007), 299–308.
12. Varbo, A., Benn, M., Tybjaerg-Hansen, A., Jorgensen, A.B., Frikke-Schmidt, R., et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 61 (2013), 427–436.
13. Chapman, M.J., Redfern, J.S., McGovern, M.E., Giral, P., Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther. 126 (2010), 314–345.
14. Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375 (2010), 1875–1884.
15. Wang, D., Liu, B., Tao, W., Hao, Z., Liu, M., Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst. Rev., 2015 CD009580.
16. Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R. 3rd, Leiter, L.A., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362 (2010), 1563–1574.
17. Keech, A., Simes, R.J., Barter, P., Best, J., Scott, R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005), 1849–1861.
18. Sacks, F.M., Carey, V.J., Fruchart, J.C., Combination lipid therapy in type 2 diabetes. N. Engl. J. Med. 363 (2010), 692–694 author reply 694–695.
19. Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis 249 (2016), 36–43.
20. Cui, Y., Blumenthal, R.S., Flaws, J.A., Whiteman, M.K., Langenberg, P., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern Med. 161 (2001), 1413–1419.
21. Pischon, T., Girman, C.J., Sacks, F.M., Rifai, N., Stampfer, M.J., et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005), 3375–3383.
22. Sigurdsson, G., Nicoll, A., Lewis, B., Conversion of very low density lipoprotein to low density lipoprotein. A metabolic study of apolipoprotein B kinetics in human subjects. J. Clin. Invest 56 (1975), 1481–1490.
23. Davidson, M.H., Rosenson, R.S., Maki, K.C., Nicholls, S.J., Ballantyne, C.M., et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler. Thromb. Vasc. Biol. 34 (2014), 1298–1306.
24. Hirose, T., Teramoto, T., Abe, K., Taneyama, T., Determinants of bezafibrate-induced improvements in LDL cholesterol in dyslipidemic patients with diabetes. J. Atheroscler. Thromb. 22 (2015), 676–684.
25. Chancharme, L., Therond, P., Nigon, F., Lepage, S., Couturier, M., et al. Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. Arterioscler. Thromb. Vasc. Biol. 19 (1999), 810–820.
26. de Graaf, J., Hak-Lemmers, H.L., Hectors, M.P., Demacker, P.N., Hendriks, J.C., et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11 (1991), 298–306.
27. Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005), 1685–1695.
28. Navab, M., Ananthramaiah, G.M., Reddy, S.T., Van Lenten, B.J., Ansell, B.J., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 45 (2004), 993–1007.
29. Arai, H., Kokubo, Y., Watanabe, M., Sawamura, T., Ito, Y., et al. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J. Atheroscler. Thromb. 20 (2013), 195–203.
30. Hoogeveen, R.C., Gaubatz, J.W., Sun, W., Dodge, R.C., Crosby, J.R., et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 1069–1077.
31. Alipour, A., Valdivielso, P., Elte, J.W., Janssen, H.W., Rioja, J., et al. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur. J. Clin. Invest 42 (2012), 702–708.
32. Irawati, D., Mamo, J.C., Soares, M.J., Slivkoff-Clark, K.M., James, A.P., Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state. Atherosclerosis 243 (2015), 236–241.
33. Masuda, D., Sugimoto, T., Tsujii, K., Inagaki, M., Nakatani, K., et al. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur. J. Clin. Invest 42 (2012), 992–999.
34. Pal, S., Semorine, K., Watts, G.F., Mamo, J., Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin. Chem. Lab. Med. 41 (2003), 792–795.
35. Taskinen, M.R., Boren, J., Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?. Curr. Atheroscler. Rep., 18, 2016, 59.
36. Du, X.M., Kim, M.J., Hou, L., Le Goff, W., Chapman, M.J., et al. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ. Res. 116 (2015), 1133–1142.
37. Favari, E., Chroni, A., Tietge, U.J., Zanotti, I., Escola-Gil, J.C., et al. Cholesterol efflux and reverse cholesterol transport. Handb. Exp. Pharmacol. 224 (2015), 181–206.
38. Salazar, M.R., Carbajal, H.A., Espeche, W.G., Leiva Sisnieguez, C.E., Balbin, E., et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am. J. Cardiol. 109 (2012), 1749–1753.
39. Salazar, M.R., Carbajal, H.A., Espeche, W.G., Aizpurua, M., Maciel, P.M., et al. Identification of cardiometabolic risk: visceral adiposity index versus triglyceride/HDL cholesterol ratio. Am. J. Med. 127 (2014), 152–157.
40. Berglund, E.D., Li, C.Y., Bina, H.A., Lynes, S.E., Michael, M.D., et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150 (2009), 4084–4093.
41. Emanuelli, B., Vienberg, S.G., Smyth, G., Cheng, C., Stanford, K.I., et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Invest 124 (2014), 515–527.
42. Galman, C., Lundasen, T., Kharitonenkov, A., Bina, H.A., Eriksson, M., et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 8 (2008), 169–174.
43. Kliewer, S.A., Mangelsdorf, D.J., Fibroblast growth factor 21: from pharmacology to physiology. Am. J. Clin. Nutr. 91 (2010), 254s–257s.
44. Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., et al. Statin-associated muscle symptoms: impact on statin therapy-european atherosclerosis society Consensus Panel statement on assessment, aetiology and management. Eur. Heart J. 36 (2015), 1012–1022.
45. Stock, J., Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group. Atherosclerosis 242 (2015), 346–350.
46. Zhao, Y.Y., Weir, M.A., Manno, M., Cordy, P., Gomes, T., et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann. Intern Med. 156 (2012), 560–569.